REGN Earnings

REGN reported its earnings on 2026-01-30, showcasing a revenue of 3.88B against an estimate of 3.82B, resulting in a 1.68% surprise. The EPS was 11.44, surpassing the expected 10.6 by 7.92%. The stock experienced a -1.07% price change on the earnings day and a 3.42% change over the next five days, reflecting market reactions to the results.

Following REGN's earnings announcement on 2026-01-30, the stock price moved by -1.07% on the day of the release. Over the subsequent five days, it saw a 3.42% change. Historically, REGN's stock price tends to shift by an average of -0.68% in the 10 days leading up to earnings and 1.62% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate REGN's annual revenue to reach 3.42B, while the EPS is projected at 10.48. These estimates reflect recent revisions, with revenue estimates revised upward by 0.12% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between REGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.12%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, REGN's stock price typically moves by -0.68% in the 10 days before its earnings and 1.62% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 10.48 and revenue of 3.42B.

The earnings call summary highlighted strong growth prospects for key products like Dupixent and EYLEA HD, along with robust financial metrics such as $4.1 billion in free cash flow and $3.8 billion returned to shareholders. Despite some unclear responses in the Q&A, the pipeline expansion and optimistic guidance on new product developments suggest positive momentum. The company's strategic focus on innovative therapies and shareholder returns further supports a positive outlook for the stock price over the next two weeks.